Amgen Dirección

Dirección controles de criterios 3/4

El CEO de Amgen es Bob Bradway , nombrado en May 2010, tiene una permanencia de 14.5 años. compensación anual total es $22.64M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de $185.11M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 7.9 años, respectivamente.

Información clave

Bob Bradway

Chief Executive Officer (CEO)

US$22.6m

Compensación total

Porcentaje del salario del CEO	7.9%
Permanencia del CEO	14.5yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	7.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bob Bradway en comparación con los beneficios de Amgen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$4b
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$23m	US$2m	US$7b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$21m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$20m	US$2m	US$7b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$20m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$8b
Jun 30 2019	n/a	n/a	US$8b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$19m	US$2m	US$8b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$17m	US$2m	US$2b

Compensación vs. Mercado: La compensación total de Bob($USD22.64M) está por encima de la media de empresas de tamaño similar en el mercado AR ($USD5.75M).

Compensación vs. Ingresos: La compensación de Bob ha sido consistente con los resultados de la empresa en el último año.

CEO

Bob Bradway (61 yo)

14.5yrs

Permanencia

US$22,643,650

Compensación

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Bradway	Chairman	14.5yrs	US$22.64m	0.12% $ 185.1m
Peter Griffith	Executive VP & CFO	4.8yrs	US$7.57m	0.0046% $ 7.3m
Esteban Santos	Executive Vice President of Operations	8.3yrs	US$7.21m	0.011% $ 18.1m
David Reese	Executive VP & CTO	less than a year	US$7.90m	0.0094% $ 14.9m
Murdo Gordon	Executive Vice President of Global Commercial Operations	6.2yrs	US$8.24m	0.0075% $ 11.8m
Matthew Busch	Chief Accounting Officer & VP of Finance	1.3yrs	sin datos	0.00062% $ 981.6k
James Bradner	Executive VP of Research & Development and Chief Scientific Officer	less than a year	sin datos	sin datos
Scott Skellenger	Senior VP & Chief Information Officer	no data	sin datos	sin datos
Justin Claeys	Vice President of Investor Relations	no data	sin datos	sin datos
Jonathan Graham	Executive VP	9.3yrs	US$7.24m	0.0046% $ 7.4m
Nancy Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	4.8yrs	sin datos	0.0013% $ 2.1m
Kave Niksefat	Senior Vice President of Global Marketing & Access	less than a year	sin datos	sin datos

4.8yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AMGND se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Bradway	Chairman	13.1yrs	US$22.64m	0.12% $ 185.1m
Robert Eckert	Lead Independent Director	11.9yrs	US$419.92k	0.0013% $ 2.1m
David Baltimore	Co-Chair of Scientific Advisory Board	no data	US$292.01k	sin datos
Charles Sigal	Co-Chair of the Scientific Advisory Board	no data	sin datos	sin datos
Amy Miles	Independent Director	4.3yrs	US$359.92k	0.000080% $ 126.7k
Charles Holley	Independent Director	7.8yrs	US$369.92k	0.00023% $ 364.1k
Greg Garland	Independent Director	11.1yrs	US$379.92k	0.0023% $ 3.6m
Ellen Kullman	Independent Director	8.1yrs	US$360.29k	0.000080% $ 126.7k
Brian Druker	Independent Director	6.5yrs	US$359.92k	0.00015% $ 237.5k
Tyler Jacks	Independent Director	12.5yrs	US$339.92k	0.00051% $ 807.4k
Wanda Austin	Independent Director	6.9yrs	US$359.92k	0.0012% $ 1.9m
S. Ishrak	Independent Director	3.3yrs	US$366.47k	0.00017% $ 269.1k

7.9yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de AMGND se considera experimentada (7.9 años de antigüedad promedio).

Amgen Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Inc. Announces Executive Changes

Amgen Inc. Announces Management Changes

Recent updates

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Amgen Inc. Announces Dividend for the Fourth Quarter of 2024, Payable on December 9, 2024

Amgen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Amgen Announces Presents Positive Top-Line Results from the Phase 3 MINT Trial Evaluating the Efficacy and Safety of UPLIZNA

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Announces Otezla®? (Apremilast) Now Available in the U.S. for Moderate to Severe Plaque Psoriasis

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q2, 2024 Results on Aug 06, 2024

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Amgen Inc. Announces Management Changes

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Amgen Inc. to Report Q4, 2022 Results on Jan 31, 2023

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad